METRONIDAZOLE JUNO metronidazole 500mg/100mL solution for injection bag Australia - English - Department of Health (Therapeutic Goods Administration)

metronidazole juno metronidazole 500mg/100ml solution for injection bag

juno pharmaceuticals pty ltd - metronidazole, quantity: 500 mg - injection, solution - excipient ingredients: water for injections; citric acid; sodium chloride; dibasic sodium phosphate - metronidazole juno is indicated for:treatment of severe anaerobic infection when oral medication is not possible or is contraindicated, when immediate anti-anaerobic therapy is required. metronidazole may be used prophylactically to prevent infection of the surgical site which may have been contaminated or potentially contaminated with anaerobic organisms. procedures in which this may be assumed to have happened include appendectomy, colonic surgery, vaginal hysterectomy, abdominal surgery in the presence of anaerobes in the peritoneal cavity and surgery performed in the presence of anaerobic septicaemia.

METRONIDAZOLE KABI metronidazole 500mg/100mL solution for injection bottle Australia - English - Department of Health (Therapeutic Goods Administration)

metronidazole kabi metronidazole 500mg/100ml solution for injection bottle

fresenius kabi australia pty ltd - metronidazole, quantity: 500 mg - injection, solution - excipient ingredients: citric acid monohydrate; water for injections; sodium chloride; dibasic sodium phosphate dodecahydrate - metronidazole intravenous infusion is indicated:,(a) for treatment of anaerobic infections in patients for whom oral administration is not possible.,(b) where immediate anti-anaerobic chemotherapy is required.,(c) where prophylactic cover is required at lower abdominal surgical sites presumed contaminated or potentially contaminated by anaerobic micro-organisms. procedures of this type include appendectomy, colonic surgery, vaginal hysterectomy, abdominal surgery in the presence of anaerobes in the peritoneal cavity and surgery performed in the presence of anaerobic septicaemia.,note: metronidazole is inactive against aerobic or facultative anaerobic bacteria.

METRONIDAZOLE NORIDEM, metronidazole 500mg/100mL solution for injection bottle Australia - English - Department of Health (Therapeutic Goods Administration)

metronidazole noridem, metronidazole 500mg/100ml solution for injection bottle

interpharma pty ltd - metronidazole, quantity: 500 mg - injection, solution - excipient ingredients: citric acid monohydrate; dibasic sodium phosphate dodecahydrate; water for injections; sodium chloride - treatment of severe anaerobic infection when oral medication is not possible or is contraindicated, when immediate antianaerobic therapy is required. metronidazole may be used prophylactically to prevent infection of the surgical site which may have been contaminated or potentially contaminated with anaerobic organisms. procedures in which this may be assumed to have happened include appendicectomy, colonic surgery, vaginal hysterectomy, abdominal surgery in the presence of anaerobes in the peritoneal cavity and surgery performed in the presence of anaerobic septicaemia.

METRONIDAZOLE Israel - English - Ministry of Health

metronidazole

lapidot medical import and marketing ltd - metronidazole - solution for infusion - metronidazole 500 mg / 100 ml - metronidazole - metronidazole - treatment and prophylaxis of infection which are or may be due to anerobic bacteria,especially bacteriodes species,including bacteriodes fragilis, fusobacterium,eurobacterium and clostridium species.

STOMORGYL 2 (150,000 IU SPIRAMYCIN & 25 MG METRONIDAZOLE PER TABLET) Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

stomorgyl 2 (150,000 iu spiramycin & 25 mg metronidazole per tablet)

boehringer ingelheim animal health australia pty. ltd. - spiramycin; metronidazole - oral tablet - spiramycin antibiotic active 150000.0 iu/tb; metronidazole antiprotozoal active 25.0 mg/tb - antibiotic & related - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - bacterial infection | infections of the oral cavity | amoxycillin sensitive bacteria | associated with viral disease | gram negative organisms | gram positive organisms | post parturient bacterial infe | primary bacterial infection | sulfadiazine sensitive bacteri | trimethoprim sensitive bacteri | tylosin sensitive bacteria

STOMORGYL 10 (750,000 IU SPIRAMYCIN & 125 MG METRONIDAZOLE PER TABLET) Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

stomorgyl 10 (750,000 iu spiramycin & 125 mg metronidazole per tablet)

boehringer ingelheim animal health australia pty. ltd. - spiramycin; metronidazole - oral tablet - spiramycin antibiotic active 750000.0 iu/tb; metronidazole antiprotozoal active 125.0 mg/tb - antibiotic & related - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - bacterial infection | infections of the oral cavity | amoxycillin sensitive bacteria | associated with viral disease | gram negative organisms | gram positive organisms | post parturient bacterial infe | primary bacterial infection | sulfadiazine sensitive bacteri | trimethoprim sensitive bacteri | tylosin sensitive bacteria

Metronidazole Gel 0.5% Australia - English - Department of Health (Therapeutic Goods Administration)

metronidazole gel 0.5%

orion laboratories pty ltd t/a perrigo australia - metronidazole, quantity: 5 mg/ml - gel - excipient ingredients: water for injections; propylene glycol; citric acid; hyetellose; dibasic sodium phosphate heptahydrate - metronidazole gel is indicated for the treatment of inflammatory papules and pustules of rosacea.

STOMORGYL 20 (1,500,000 IU SPIRAMYCIN & 250 MG METRONIDAZOLE PER TABLET) Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

stomorgyl 20 (1,500,000 iu spiramycin & 250 mg metronidazole per tablet)

boehringer ingelheim animal health australia pty. ltd. - spiramycin; metronidazole - oral tablet - spiramycin antibiotic active 1500000.0 iu/tb; metronidazole antiprotozoal active 250.0 mg/tb - antibiotic & related - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - bacterial infection | infections of the oral cavity | amoxycillin sensitive bacteria | associated with viral disease | gram negative organisms | gram positive organisms | post parturient bacterial infe | primary bacterial infection | sulfadiazine sensitive bacteri | trimethoprim sensitive bacteri | tylosin sensitive bacteria

Rodogyl Tablet, film coated 0.75MIU/125mg Malta - English - Medicines Authority

rodogyl tablet, film coated 0.75miu/125mg

sanofi malta limited - metronidazole, spiramycin - film-coated tablet - metronidazole 125 milligram(s) ; spiramycin 750000 international unit(s) - antibacterials for systemic use

METRONIDAZOLE gel United States - English - NLM (National Library of Medicine)

metronidazole gel

sandoz inc. - metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e) - metronidazole 10 mg in 1 g - metronidazole gel usp, 1% is indicated for the topical treatment of inflammatory lesions of rosacea. metronidazole gel usp, 1% is contraindicated in patients with a history of  hypersensitivity to metronidazole or to any other ingredient in the formulation. risk summary available data have not established an association with metronidazole use during pregnancy and major birth defects, miscarriage or other adverse maternal or fetal outcomes. no fetotoxicity was observed after oral administration of metronidazole in pregnant rats or mice. the available data do not allow the calculation of relevant comparisons between the systemic exposures of metronidazole observed in animal studies to the systemic exposures that would be expected in humans after topical use of metronidazole gel usp, 1%. the background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. risk summary it is not known whether metronidazole is present in human milk after topical administration. published literature reports the presence of metronidazole in human milk after oral administration. there are reports of diarrhea and candida infection in breastfed infants of mothers receiving oral treatment with metronidazole. there are no data on the effects of metronidazole on milk production. because of the potential for serious adverse reactions, advise patients that breastfeeding is not recommended during treatment with  metronidazole gel usp, 1%. safety and effectiveness in pediatric patients have not been established. sixty-six subjects aged 65 years and older were treated with metronidazole gel usp, 1% in the clinical study.   no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.